Regulating the p53 pathway: in vitro hypotheses, in vivo veritas, Nature Reviews Cancer, vol.55, issue.12, pp.909-932, 2006. ,
DOI : 10.1002/gcc.20310
Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and??immortalization, Genes & Development, vol.12, issue.15, pp.2424-2457, 1998. ,
DOI : 10.1101/gad.12.15.2424
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC317045
Intrinsic tumour suppression, Nature, vol.35, issue.7015, pp.307-322, 2004. ,
DOI : 10.1038/nature03098
URL : http://www.nature.com/nature/journal/v432/n7015/pdf/nature03098.pdf
Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development, Cancer Cell, vol.30, issue.2, pp.367-81, 2010. ,
DOI : 10.1016/j.ccell.2016.07.007
MicroRNAs in the p53 network: micromanagement of tumour suppression, Nature Reviews Cancer, vol.205, issue.9, pp.613-639, 2012. ,
DOI : 10.1038/nrc3318
USP10 Regulates p53 Localization and Stability by Deubiquitinating p53, Cell, vol.140, issue.3, pp.384-96, 2010. ,
DOI : 10.1016/j.cell.2009.12.032
URL : http://doi.org/10.1016/j.cell.2009.12.032
ATM-Dependent Downregulation of USP7/HAUSP by PPM1G Activates p53 Response to DNA Damage, Molecular Cell, vol.45, issue.6, pp.801-814, 2012. ,
DOI : 10.1016/j.molcel.2012.01.021
ARF-BP1/Mule Is a Critical Mediator of the ARF Tumor Suppressor, Cell, vol.121, issue.7, pp.1071-83, 2005. ,
DOI : 10.1016/j.cell.2005.03.037
International Agency for Research on Cancer, World Health Organization . WHO classification of tumours of haematopoietic and lymphoid tissues, International Agency for Research on Cancer, 2008. ,
Mutations in Hairy-Cell Leukemia, New England Journal of Medicine, vol.364, issue.24, pp.2305-2320, 2011. ,
DOI : 10.1056/NEJMoa1014209
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma, Blood, vol.121, issue.12, pp.2253-63, 2013. ,
DOI : 10.1182/blood-2012-06-435842
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study, Blood, vol.126, issue.22, pp.2466-74, 2015. ,
DOI : 10.1182/blood-2015-05-647602
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways, Proceedings of the National Academy of Sciences, vol.319, issue.5870, p.13520, 2008. ,
DOI : 10.1126/science.1153629
The Genetic Landscape of Diffuse Large B-Cell Lymphoma, Seminars in Hematology, vol.52, issue.2, pp.67-76, 2015. ,
DOI : 10.1053/j.seminhematol.2015.01.005
Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms, British Journal of Haematology, vol.80, issue.2, pp.286-93, 2007. ,
DOI : 10.1073/pnas.1732008100
Multiple factor analysis (AFMULT package) Comput Statist Data Anal, pp.121-161, 1994. ,
DOI : 10.1016/0167-9473(94)90135-x
p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV, British Journal of Haematology, vol.95, issue.1, pp.53-62, 2005. ,
DOI : 10.1093/emboj/17.16.4657
Co-occurrence of MYC amplification and TP53 mutations in human cancer, Nature Genetics, vol.149, issue.2, pp.104-110, 2016. ,
DOI : 10.1038/ng.3468
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis, Genes & Development, vol.13, issue.20, pp.2658-69, 1999. ,
DOI : 10.1101/gad.13.20.2658
A MYC???aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer, Nature Medicine, vol.10, issue.7, 2016. ,
DOI : 10.1158/0008-5472.CAN-14-1726
Slaying RAS with a synthetic lethal weapon, Cell Research, vol.438, issue.2, pp.119-140, 2010. ,
DOI : 10.1056/NEJMoa0900212
Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy, Blood, vol.123, issue.5, pp.632-641, 2014. ,
DOI : 10.1182/blood-2013-05-504340
mutation status and bortezomib therapy for relapsed multiple myeloma, British Journal of Haematology, vol.120, issue.6, pp.905-913, 2015. ,
DOI : 10.1111/bjh.13258
B-cell acute lymphoblastic leukaemia: towards understanding its cellular origin, BioEssays, vol.6, issue.6, pp.600-609, 2009. ,
DOI : 10.1038/nature07602
Targeting RAS signalling pathways in cancer therapy, Nature Reviews Cancer, vol.3, issue.1, pp.11-22, 2003. ,
DOI : 10.1038/nrc969
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2, Science, vol.303, issue.5659, pp.844-852, 2004. ,
DOI : 10.1126/science.1092472
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program, pp.2630-2670, 2013. ,
The molecular classification of multiple myeloma, Blood, vol.108, issue.6, pp.2020-2028, 2006. ,
DOI : 10.1182/blood-2005-11-013458
Gene abnormalities in multiple myeloma; the relevance of TP53, MDM2, and CDKN2A, pp.529-566, 2003. ,
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer, Cancer Discovery, vol.5, issue.11, pp.1137-54, 2015. ,
DOI : 10.1158/2159-8290.CD-15-0714
p53 downregulates the Fanconi anaemia DNA repair pathway, Nature Communications, vol.39, p.11091, 2016. ,
DOI : 10.1038/ncomms11091
URL : https://hal.archives-ouvertes.fr/hal-01300933
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance, Blood, vol.124, issue.10, pp.1626-1662, 2014. ,
DOI : 10.1182/blood-2014-01-548800
CRISPR-Cas9???based target validation for p53-reactivating model compounds, Nature Chemical Biology, vol.21, issue.1, pp.22-30, 2016. ,
DOI : 10.1016/j.molcel.2010.02.037
ABT-737 is highly effective against molecular subgroups of multiple myeloma, Blood, vol.118, issue.14, pp.3901-3911, 2011. ,
DOI : 10.1182/blood-2010-11-317438
ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents, Clinical Cancer Research, vol.17, issue.18, pp.5973-81, 2011. ,
DOI : 10.1158/1078-0432.CCR-11-0955
The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism, Blood, vol.127, issue.25, pp.3215-3239, 2016. ,
DOI : 10.1182/blood-2016-01-688796
Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach, Experimental Hematology, vol.43, issue.2, pp.89-99, 2015. ,
DOI : 10.1016/j.exphem.2014.10.004
Abstract N 310: the oncolytic measles virus preferentially infects p53 abnormal myeloma cells [Internet] Available from: https, 2016. ,
Handling missing values in multiple factor analysis, Food Quality and Preference, vol.30, issue.2, pp.77-85, 2013. ,
DOI : 10.1016/j.foodqual.2013.04.013
URL : https://hal.archives-ouvertes.fr/hal-01070888
K-Ras mutations and Nras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements, Cancer Feb, vol.15106, issue.4, pp.950-956, 2006. ,
DOI : 10.1002/cncr.21687
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial, Blood, vol.109, issue.8, pp.3189-97, 2007. ,
DOI : 10.1182/blood-2006-10-051912
CDKN2 Gene Deletion as Poor Prognosis Predictor Involved in the Progression of Adult B-Lineage Acute Lymphoblastic Leukemia Patients, Journal of Cancer, vol.6, issue.11, pp.1114-1134, 2015. ,
DOI : 10.7150/jca.11959
Genome-Wide DNA Copy Number Analysis of Acute Lymphoblastic Leukemia Identifies New Genetic Markers Associated with Clinical Outcome, PLOS ONE, vol.47, issue.6, pp.2016-0148972 ,
DOI : 10.1371/journal.pone.0148972.s003
ATM gene deletion in patients with adult acute lymphoblastic leukemia, Cancer, vol.53, issue.5, pp.1057-62, 2000. ,
DOI : 10.1002/(SICI)1097-0142(20000301)88:5<1057::AID-CNCR16>3.0.CO;2-6
ATM gene alterations in childhood acute lymphoblastic leukemias, Human Mutation, vol.21, issue.5, p.554, 2003. ,
DOI : 10.1002/humu.9140
TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis, Blood, vol.124, issue.2, pp.251-259, 2014. ,
DOI : 10.1182/blood-2014-02-558833
Long-term outcome of a pediatric-inspired regimen used for adults aged 18???50 years with newly diagnosed acute lymphoblastic leukemia, Leukemia, vol.92, issue.3, pp.526-560, 2015. ,
DOI : 10.1002/(SICI)1097-0142(19990315)85:6<1395::AID-CNCR25>3.0.CO;2-2
B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures, Leukemia, vol.63, issue.11, pp.2160-2167, 2009. ,
DOI : 10.1007/s00277-004-0879-2
Aberrations of MYC Are a Common Event in B-Cell Prolymphocytic Leukemia, American Journal of Clinical Pathology, vol.142, issue.3, pp.347-54, 2014. ,
DOI : 10.1309/AJCPUBHM8U7ZFLOB
p53 Abnormalities in B-cell prolymphocytic leukemia, Blood Mar, vol.1589, issue.6, pp.2015-2038, 1997. ,
A Multicentric Study of 41 Cases of B-Prolymphocytic Leukemia: Two Evolutive Forms: The Groupe Fran??ais d'H??matologie Cellulaire, Leukemia & Lymphoma, vol.33, issue.1, pp.981-988, 2001. ,
DOI : 10.1111/j.1365-2141.1986.tb07575.x
The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells, Blood, vol.123, issue.19, pp.2988-96, 2014. ,
DOI : 10.1182/blood-2013-07-517177
Landscape of somatic mutations and clonal evolution in mantle cell lymphoma, Proceedings of the National Academy of Sciences, vol.110, issue.4, pp.18250-18255, 2013. ,
DOI : 10.1073/pnas.1205299110
Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations, Haematologica, vol.93, issue.5, pp.680-687, 2008. ,
DOI : 10.3324/haematol.12330
High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma, Blood, vol.126, issue.5, pp.604-615, 2015. ,
DOI : 10.1182/blood-2015-02-628792
Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome, Blood, vol.105, issue.11, pp.4445-54, 2005. ,
DOI : 10.1182/blood-2004-10-3907
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma, Cancer Cell, vol.3, issue.2, pp.185-97, 2003. ,
DOI : 10.1016/S1535-6108(03)00028-X
Absence of ATM hypermethylation in mantle cell and follicular lymphoma, Leukemia, vol.103, issue.5, pp.880-882, 2005. ,
DOI : 10.1038/sj.leu.2403676
Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma, Proceedings of the National Academy of Sciences, vol.62, issue.15, pp.5372-5379, 2003. ,
DOI : 10.1038/sj.leu.2402540
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma, Proceedings of the National Academy of Sciences, vol.25, issue.14, pp.2352-2359, 2006. ,
DOI : 10.1093/nar/25.14.2745
p53 and mdm2 in mantle cell lymphoma in leukemic phase, Haematologica, vol.87, issue.11, pp.1141-50, 2002. ,
Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma, Int J Oncol Mar, vol.136, issue.3, pp.699-706, 2010. ,
Impact of TP53 mutation and 17p deletion in mantle cell lymphoma, Leukemia, vol.93, issue.12, pp.1904-1912, 2011. ,
DOI : 10.1182/blood-2008-01-129783
TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage, Medical Oncology, vol.93, issue.3, pp.2166-73, 2011. ,
DOI : 10.1007/s12032-011-0096-5
p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis, pp.4302-4312, 1996. ,
p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas, Blood, vol.87, issue.8, pp.3351-3360, 1996. ,
Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309, Haematologica, vol.92, issue.4, pp.574-579, 2007. ,
DOI : 10.3324/haematol.10891
The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index, Haematologica, vol.97, issue.9, pp.1422-1452, 2012. ,
DOI : 10.3324/haematol.2011.055715
Mantle cell lymphoma epidemiology: a population-based study in France, Annals of Hematology, vol.91, issue.11, pp.1327-1360, 2014. ,
DOI : 10.1007/s00277-014-2049-5
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network, The Lancet, vol.388, issue.10044, pp.565-75, 2016. ,
DOI : 10.1016/S0140-6736(16)00739-X
Mutations driving CLL and their evolution in progression and relapse, Nature, vol.339, issue.7574, pp.525-555, 2015. ,
DOI : 10.1038/nature15395
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4815041
Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia. Clin Cancer Res, pp.3791-802, 2012. ,
Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL, Blood, vol.126, issue.18, pp.2110-2117, 2015. ,
DOI : 10.1182/blood-2015-05-647578
Inactivation Significantly Reduces Survival in Patients Treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 Trial, Journal of Clinical Oncology, vol.30, issue.36, pp.4524-4556, 2012. ,
DOI : 10.1200/JCO.2011.41.0852
High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations, Blood, vol.120, issue.24, pp.4783-94, 2012. ,
DOI : 10.1182/blood-2012-04-423517
Mutation and Survival in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.28, issue.29, pp.4473-4482, 2010. ,
DOI : 10.1200/JCO.2009.27.8762
Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment, Leukemia, vol.12, issue.6, pp.1159-61, 2006. ,
DOI : 10.1038/sj.leu.2404195
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.26, pp.1910-1916, 2000. ,
DOI : 10.1056/NEJM200012283432602
Comprehensive analysis of disease-related genes in chronic lymphocytic leukemia by multiplex pcr-based next generation sequencing Available from, PLoS One Jun, vol.810, issue.6, 2015. ,
p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation, Blood, vol.98, issue.3, pp.814-836, 2001. ,
DOI : 10.1182/blood.V98.3.814
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up, Blood, vol.112, issue.8, pp.3322-3331, 2008. ,
DOI : 10.1182/blood-2008-04-154070
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia, Blood, vol.126, issue.4, pp.445-53, 2015. ,
DOI : 10.1182/blood-2015-02-585042
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial, Blood, vol.127, issue.2, pp.208-223, 2016. ,
DOI : 10.1182/blood-2015-06-651125
Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry, The Lancet Oncology, vol.16, issue.9, pp.1111-1133, 2015. ,
DOI : 10.1016/S1470-2045(15)00169-2
MYC rearrangements in histologically progressed follicular lymphomas, Blood Aug, vol.180, issue.3, pp.758-67, 1992. ,
translocation in t(14;18) positive follicular lymphoma at presentation: An adverse prognostic indicator?, Leukemia & Lymphoma, vol.127, issue.3, pp.470-476, 2008. ,
DOI : 10.1038/modpathol.3800500
INK4a/ARFLocus Alterations in Human Non-Hodgkin's Lymphomas Mainly Occur in Tumors with Wild-Type p53 Gene, The American Journal of Pathology, vol.156, issue.6, pp.1987-96, 2000. ,
DOI : 10.1016/S0002-9440(10)65071-7
Inactivation of the CDKN2A Tumor-Suppressor Gene by Deletion or Methylation Is Common at Diagnosis in Follicular Lymphoma and Associated with Poor Clinical Outcome, Clinical Cancer Research, vol.20, issue.6, pp.1676-86, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2175
Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma, Blood, vol.123, issue.11, pp.1681-90, 2014. ,
DOI : 10.1182/blood-2013-05-500595
Comprehensive analysis of copy number and allele status identifies multiple chromosome defects underlying follicular lymphoma pathogenesis. Clin Cancer Res, pp.4777-85, 2007. ,
Prognostic significance of secondary cytogenetic alterations in follicular lymphomas, Genes, Chromosomes and Cancer, vol.316, issue.12, pp.1038-1086, 2008. ,
DOI : 10.1002/gcc.20606
Mutation of the ATM Gene is Not Involved in the Pathogenesis of Either Follicle Center Lymphoma or its Transformation to Higher-grade Lymphoma, Leukemia & Lymphoma, vol.43, issue.5, pp.1079-85, 2002. ,
DOI : 10.1080/10428190290021623
Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement, Haematologica, vol.87, issue.9, pp.908-925, 2002. ,
The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival, Blood Oct, vol.15112, issue.8, pp.3126-3135, 2008. ,
Updated 6 year follow-up of the PRIMA study confirms the benefit of 2-year rituximab maintenance in follicular lymphoma patients responding to frontline immunochemotherapy, Blood, vol.122, issue.21, p.509, 2013. ,
The genetic landscape of mutations in Burkitt lymphoma, Nature Genetics, vol.57, issue.12, pp.1321-1326, 2012. ,
DOI : 10.1126/science.1145720
Expression of p16INK4A and p14ARF in hematological malignancies, Leukemia, vol.13, issue.11, pp.1760-1769, 1999. ,
DOI : 10.1038/sj.leu.2401557
Inactivation of the ARF???MDM-2???p53 pathway in sporadic Burkitt's lymphoma in children, Leukemia, vol.18, issue.3, pp.584-592, 2003. ,
DOI : 10.1038/sj.leu.2403254
TP53 pathway analysis in paediatric Burkitt lymphoma reveals increased MDM4 expression as the only TP53 pathway abnormality detected in a subset of cases, British Journal of Haematology, vol.18, issue.6, pp.763-71, 2012. ,
DOI : 10.1111/j.1365-2141.2012.09243.x
The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with doseintensive chemotherapy including rituximab, Br J Haematol Feb, vol.1, issue.1723, pp.428-466, 2016. ,
Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by arraybased , high resolution, single nucleotide polymorphism analysis, pp.2047-55, 2010. ,
Overall Survival in Aggressive B-Cell Lymphomas Is Dependent on the Accumulation of Alterations in p53, p16, and p27, The American Journal of Pathology, vol.159, issue.1, pp.205-218, 2001. ,
DOI : 10.1016/S0002-9440(10)61686-0
p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia., Proceedings of the National Academy of Sciences, vol.88, issue.12, pp.5413-5420, 1991. ,
DOI : 10.1073/pnas.88.12.5413
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC51883
High Resolution Genome-Wide Analysis of Chromosomal Alterations in Burkitt's Lymphoma, PLoS ONE, vol.446, issue.9, p.7089, 2009. ,
DOI : 10.1371/journal.pone.0007089.s013
DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control, Nature Genetics, vol.47, issue.11, pp.1316-1341, 2015. ,
DOI : 10.1073/pnas.1732008100
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial, Blood, vol.124, issue.26, pp.3870-3879, 2014. ,
DOI : 10.1182/blood-2014-03-563627
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing, Proceedings of the National Academy of Sciences, vol.79, issue.1, pp.3879-84, 2012. ,
DOI : 10.1182/blood-2007-07-100115
Analysis of the coding genome of diffuse large B-cell lymphoma, Nature Genetics, vol.96, issue.9, pp.830-837, 2011. ,
DOI : 10.1093/bioinformatics/btl646
Aberrations of the p53 pathway components p53, MDM2 and CDKN2A appear independent in diffuse large B cell lymphoma, Leukemia, vol.13, issue.3, pp.453-462, 1999. ,
DOI : 10.1038/sj.leu.2401315
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study, Blood, vol.116, issue.7, pp.1092-104, 2010. ,
DOI : 10.1182/blood-2009-10-247122
URL : https://hal.archives-ouvertes.fr/ensl-00816038
ATM mutations are associated with inactivation of theARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma, Blood Aug, vol.15100, issue.4, pp.1430-1437, 2002. ,
Deletions at 11q23 in different lymphoma subtypes, Haematologica, vol.85, issue.9, pp.908-920, 2000. ,
DOI : 10.1038/sj.leu.2401405
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma, Genes, Chromosomes and Cancer, vol.110, issue.3, pp.251-67, 2016. ,
DOI : 10.1002/gcc.22328
URL : https://hal.archives-ouvertes.fr/hal-01237083
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study, Blood, vol.120, issue.19, pp.3986-96, 2012. ,
DOI : 10.1182/blood-2012-05-433334
Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma, Blood Nov 15, vol.90, issue.10, pp.4078-91, 1997. ,
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program, Blood, vol.121, issue.20, pp.4021-4052, 2013. ,
DOI : 10.1182/blood-2012-10-460063
Helicobacter pylori eradication therapy for high-grade mucosa-associated lymphoid tissue lymphomas of the stomach with analysis of p53 and K-ras alteration and microsatellite instability, International Journal of Oncology, vol.18, issue.6, pp.1207-1219, 2001. ,
DOI : 10.3892/ijo.18.6.1207
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome, Blood, vol.117, issue.5, pp.1595-604, 2011. ,
DOI : 10.1182/blood-2010-01-264275
Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities, Modern Pathology, vol.23, issue.5, pp.651-60, 2012. ,
DOI : 10.1038/modpathol.2011.213
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3341516
Detection and clinical significance of genes in primary gastrointestinal MALT lymphoma, Tumor Biology, vol.114, issue.12, pp.3223-3231, 2013. ,
DOI : 10.1007/s13277-013-1421-8
Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas, Molecular Pathology, vol.51, issue.5, pp.262-269, 1998. ,
DOI : 10.1136/mp.51.5.262
Molecular Analysis of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma of Ocular Adnexa, Leukemia & Lymphoma, vol.24, issue.1-2, pp.207-221, 2001. ,
DOI : 10.1006/viro.1993.1224
The gastric marginal zone B-cell lymphoma of MALT type, Blood Jul, vol.1596, issue.2, pp.410-419, 2000. ,
Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation, Leukemia, vol.78, issue.6, pp.1334-1374, 2014. ,
DOI : 10.1016/j.ccr.2009.01.007
Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing, Clinical Cancer Research, vol.21, issue.18, pp.4174-83, 2015. ,
DOI : 10.1158/1078-0432.CCR-14-2759
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490180
Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group, Blood, vol.116, issue.9, pp.1479-88, 2010. ,
DOI : 10.1182/blood-2010-02-267476
High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma, British Journal of Haematology, vol.100, issue.6, pp.712-738, 2012. ,
DOI : 10.1111/j.1365-2141.2012.09226.x
The Kr??ppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma, Leukemia, vol.28, issue.2, pp.503-510, 2015. ,
DOI : 10.1038/ng.892
and other pathways regulating marginal zone development, The Journal of Experimental Medicine, vol.220, issue.9, pp.1537-51, 2012. ,
DOI : 10.1016/j.str.2005.07.015
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3428941
Splenic marginal zone lymphoma: a population-based study on the 2001???2008 incidence and survival in the United States, Leukemia & Lymphoma, vol.47, issue.7, pp.1380-1386, 2013. ,
DOI : 10.1038/nature01322
Exome Sequencing in Classic Hairy Cell Leukaemia Reveals Widespread Variation in Acquired Somatic Mutations between Individual Tumours Apart from the Signature BRAF V(600)E Lesion, PLOS ONE, vol.128, issue.238, p.149162, 2016. ,
DOI : 10.1371/journal.pone.0149162.t004
Hairy cell leukemia is characterized by clonal chromosome abnormalities clustered to specific regions, Blood May, vol.1, issue.839, pp.2637-2682, 1994. ,
Genome-wide high resolution DNA profiling of hairy cell leukaemia, British Journal of Haematology, vol.119, issue.4, pp.566-575, 2013. ,
DOI : 10.1111/bjh.12393
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to singleagent cladribine and with more aggressive behavior, pp.4696-702, 2009. ,
Chromosomal gains and losses are uncommon in hairy cell leukemia, Cancer Genetics and Cytogenetics, vol.128, issue.2, pp.164-171, 2001. ,
DOI : 10.1016/S0165-4608(01)00415-0
P53 mutations in hairy cell leukemia, Leukemia, vol.14, issue.4, pp.706-717, 2000. ,
DOI : 10.1038/sj.leu.2401721
Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia, British Journal of Haematology, vol.116, issue.Suppl. 2, pp.390-400, 2014. ,
DOI : 10.1111/bjh.12908
MYD88 L265P Somatic Mutation in Waldenstr??m's Macroglobulinemia, New England Journal of Medicine, vol.367, issue.9, pp.826-859, 2012. ,
DOI : 10.1056/NEJMoa1200710
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom's macroglobulinemia, Haematologica, vol.98, issue.4, pp.649-54, 2013. ,
DOI : 10.3324/haematol.2012.070458
Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-??B Signaling Pathways in Waldenstrom's Macroglobulinemia, Cancer Research, vol.69, issue.8, pp.3579-88, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-3701
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis, Blood, vol.123, issue.11, pp.1637-1683, 2014. ,
DOI : 10.1182/blood-2013-09-525808
International prognostic scoring system for Waldenström macroglobulinemia, pp.4163-70, 2009. ,
DOI : 10.1182/blood-2008-08-174961
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation, Oncotarget, vol.6, issue.27, pp.24205-24222, 2015. ,
DOI : 10.18632/oncotarget.4434
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma, Journal of Clinical Oncology, vol.33, issue.33, pp.3911-3931, 2015. ,
DOI : 10.1200/JCO.2014.59.1503
Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma, Leukemia, vol.92, issue.8, pp.1725-1760, 2014. ,
DOI : 10.1182/blood-2006-08-040410
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126852
mutations occur rarely in a subset of multiple myeloma patients, British Journal of Haematology, vol.32, issue.6, pp.925-958, 2008. ,
DOI : 10.1111/j.1365-2141.2008.07281.x
Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome, Blood, vol.109, issue.8, pp.3489-95, 2007. ,
DOI : 10.1182/blood-2006-08-040410
Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma, Leukemia, vol.92, issue.3, pp.633-642, 2016. ,
DOI : 10.1200/JCO.2011.39.6820
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation, Clinical Lymphoma Myeloma and Leukemia, vol.15, issue.11, pp.687-93, 2015. ,
DOI : 10.1016/j.clml.2015.07.641
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644689
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group, Journal of Clinical Oncology, vol.33, issue.26, pp.2863-2872, 2015. ,
DOI : 10.1200/JCO.2015.61.2267
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846284
High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis, Human Mutation, vol.83, issue.3, pp.212-236, 2001. ,
DOI : 10.1002/humu.1177
Genetic aberrations and survival in plasma cell leukemia, Leukemia, vol.156, issue.5, pp.1044-52, 2008. ,
DOI : 10.1038/leu.2008.4
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893817
Rearrangements of the c-myc oncogene are present in 15% of primary human multiple myeloma tumors, Blood, vol.98, issue.10, pp.3082-3088, 2001. ,
DOI : 10.1182/blood.V98.10.3082
in plasma cell leukemia, Genes, Chromosomes and Cancer, vol.108, issue.7, pp.624-660, 2009. ,
DOI : 10.1002/gcc.20670
Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles, American Journal of Hematology, vol.118, issue.Suppl 1, pp.16-23, 2013. ,
DOI : 10.1002/ajh.23339
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du My??lome, Journal of Clinical Oncology, vol.34, issue.18, pp.2125-2157, 2016. ,
DOI : 10.1200/JCO.2015.63.1929
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, Oncotarget, vol.6, issue.19, pp.17543-58, 2015. ,
DOI : 10.18632/oncotarget.4028
Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization, Cancer Genetics and Cytogenetics, vol.156, issue.2, pp.150-153, 2005. ,
DOI : 10.1016/j.cancergencyto.2004.05.004
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature, Oncotarget Feb, vol.8, issue.716, pp.21353-61, 2016. ,
Trends in survival of patients with primary plasma cell leukemia: a population-based analysis, Blood, vol.124, issue.6, pp.907-919, 2014. ,
DOI : 10.1182/blood-2014-03-565051
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group, American Journal of Hematology, vol.11, issue.2, pp.145-50, 2014. ,
DOI : 10.1002/ajh.23600